A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 66,713 shares of CHRS stock, worth $54,037. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,713
Previous 63,874 4.44%
Holding current value
$54,037
Previous $88,000 38.64%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$0.81 - $1.66 $2,299 - $4,712
2,839 Added 4.44%
66,713 $54,000
Q4 2024

Feb 14, 2025

BUY
$0.67 - $1.71 $2,794 - $7,132
4,171 Added 6.99%
63,874 $88,000
Q3 2024

Nov 14, 2024

BUY
$0.99 - $1.8 $5,951 - $10,821
6,012 Added 11.2%
59,703 $62,000
Q2 2024

Aug 14, 2024

BUY
$1.58 - $2.51 $84,831 - $134,764
53,691 New
53,691 $92,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $63M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Mirae Asset Global Etfs Holdings Ltd. Portfolio

Follow Mirae Asset Global Etfs Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.